- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
FDC reported Q2 revenue down 7.9% to 473 Cr and PAT down 60.6% to 28 Cr, mainly due to lower domestic sales and strategic R&D/employee costs. Export formulations grew 3.5% in Q2, with US supplies showing recovery. The company received US FDA approvals for two ophthalmic solutions. Electral rose to 15th rank in IPM.